The study of tumour-specific antigens (TSAs) as targets for antitumour therapies has
accelerated within the past decade. The most commonly studied class of TSAs are those …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Immune-checkpoint inhibition provides an unmatched level of durable clinical efficacy in
various malignancies. Such therapies promote the activation of antigen-specific T cells …

Recent advances in immune checkpoint blockade therapy have revolutionized the treatment
of cancer. Tumor-specific antigens that are generated by somatic mutation, neoantigens, can …

Chronic myeloid leukaemia (CML) was the first neoplastic disease for which knowledge of
the genotype led to a rationally designed therapy. As a result of its well known …

Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …

Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

Around 15 years ago, imatinib mesylate (Gleevec® or Glivec®, Novartis, Switzerland)
became the very first'targeted'anticancer drug to be clinically approved. This drug constitutes …

Chronic myeloid leukemia (CML) has become a model in research and management among
malignant disorders. Since the discovery of the presence of a unique and constant …

Tumor neoantigens play an important role in current cancer immunotherapies. The most
commonly studied class of tumor neoantigens contains those derived from single-nucleotide …